SurgeryHumansPancreatic FistulaPancreaticoduodenectomyMaleNeoadjuvant Therapy
A risk-adjusted evaluation of the impact of neoadjuvant therapy on pancreatic fistula development after pancreatoduodenectomy.
Max Judish, Samuele Cannas, Fabio Casciani, Asmita Chopra, Neha Shetty, Rudy El Asmar, Giuseppe Malleo, Gabriella Lionetto, Niccolò Napoli, Emanuele F Kauffmann, Michael Ginesini, Ugo Boggi, Roberto Salvia, Amer H Zureikat, Charles M Vollmer
Published: 202610.1016/j.surg.2025.109819
Abstract
BACKGROUND: Most patients undergoing pancreatoduodenectomy after neoadjuvant therapy for periampullary malignancies have pancreatic adenocarcinoma, a known protective factor against postoperative pancreatic fistula. Accordingly, the perceived lower p…
Preview only. Read the full abstract at the source